Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis

Lota Ozola, Elīna Aleksejeva, Diāna Stoldere (Corresponding Author), Zane Dāvidsone, Ruta Šantere, Ineta Grantiņa, Ieva Cīrule, Alvils Krams

Research output: Contribution to journalLetterpeer-review

2 Citations (Scopus)

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) is classified as an antineutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis. It is a multisystem disorder and can affect every organ system. EGPA is a rare disease, with an estimated prevalence of 1/70,000–100,000 in Europe. As its onset usually occurs in adulthood, data from pediatric patients are limited. We present here a very rare practical EGPA clinical case involving a pediatric patient. Presently, data on mepolizumab usage in pediatric patients are limited, with only a few case reports published.

Original languageEnglish
Pages (from-to)973-979
JournalPediatric Pulmonology
Volume58
Issue number3
DOIs
Publication statusPublished - Mar 2023

Keywords*

  • mepolizumab in pediatrics
  • pediatric EGPA
  • small vessel vasculitis

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint

Dive into the research topics of 'Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis'. Together they form a unique fingerprint.

Cite this